FDA lifts partial hold on Blueprint's CDK2 inhibitor
The FDA has lifted a partial clinical hold on Blueprint Medicines’ early-stage cancer drug, clearing the way for the biotech to dose new patients.
Blueprint flagged the hold last month, which it said was imposed due to reports of side effects related to vision. A “limited number of patients” experienced what it described as “transient, reversible episodes of light sensitivity and blurred vision” after taking BLU-222. While the FDA allowed patients already enrolled in the trial to keep receiving the drug, no new patients could be enrolled.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.